{"id":"NCT02100631","sponsor":"Bavarian Nordic","briefTitle":"A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults","officialTitle":"A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 O1 Serotype Inaba Strain CVD 103-HgR","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2015-02","completion":"2015-06","firstPosted":"2014-04-01","resultsPosted":"2021-04-30","lastUpdate":"2023-06-28"},"enrollment":398,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Cholera"],"interventions":[{"type":"BIOLOGICAL","name":"PXVX0200","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"PXVX0200 in Older Adults","type":"EXPERIMENTAL"},{"label":"Placebo in Older Adults","type":"PLACEBO_COMPARATOR"},{"label":"Historical Control: Adults Aged 18-45","type":"OTHER"}],"summary":"Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.","primaryOutcome":{"measure":"Seroconversion Rate at Day 11","timeFrame":"Day 11","effectByArm":[{"arm":"PXVX0200 in Older Adults","deltaMin":90.4,"sd":null},{"arm":"Historical Control: Adults Aged 18-45","deltaMin":93.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"46 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":["30772070"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":296},"commonTop":["Fatigue","Back Pain","Decreased Appetite","Flatulence","Rash"]}}